Preclinical pharmacokinetic characterization of amdizalisib, a novel PI3Kδ inhibitor for the treatment of hematological malignancies

Amdizalisib, also named HMPL-689, a novel selective and potent PI3Kδ inhibitor, is currently under Phase II clinical development in China for treating hematological malignancies. The preclinical pharmacokinetics (PK) of amdizalisib were extensively characterized in vitro and in vivo to support the f...

Full description

Saved in:
Bibliographic Details
Main Authors: Shuwen Jiang (Author), Xiangkun Li (Author), Weifang Xue (Author), Sumei Xia (Author), Jian Wang (Author), Yang Sai (Author), Guangxiu Dai (Author), Weiguo Su (Author)
Format: Book
Published: Frontiers Media S.A., 2024-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available